|
Video: What is a Stock Split?
|
|
Virios Therapeutics is a development-stage biotechnology company, which engages in the improvement of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. Co.'s primary candidate, IMC-1, is a proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. According to our Virios Therapeutics stock split history records, Virios Therapeutics has had 0 splits. | |
|
Virios Therapeutics (VIRI) has 0 splits in our Virios Therapeutics stock split history database.
Looking at the Virios Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Virios Therapeutics shares, starting with a $10,000 purchase of VIRI, presented on a split-history-adjusted basis factoring in the complete Virios Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/18/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$10.40 |
|
End price/share: |
$0.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.48% |
|
Average Annual Total Return: |
-60.29% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$451.79 |
|
Years: |
3.35 |
|
|
|
|
|